Evidence map›Paper›PMID 32774692›Full record

ReviewAmerican journal of translational research2020

Update on the epidemiology, genetics, and therapeutic options of hyperuricemia.

Lijun Li, Yipeng Zhang, Changchun Zeng

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06084585 (A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia), which is not on this map. Cited by 134 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 7 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06084585 naunknown statusnot on this mapstarted 2023, after this paper: background citation

A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

TypeinterventionalSponsorAmway (China) R&D CenterRan2023 to 2024Enrolled180ConditionsHyperuricemiaArmsStudy Product A (High-dose 2X), Study Product B (Low-dose X), Placebo
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 7 syntheses or guidelines pooled it, 200 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lijun LiDepartment of Quality Control, Shenzhen Longhua District Central Hospital, Guangdong Medical University Shenzhen 518110, Guangdong, P. R. China.
Yipeng ZhangDepartment of Clinical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University Shenzhen 518110, Guangdong, P. R. China.
Changchun ZengDepartment of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University Shenzhen 518110, Guangdong, P. R. China.
Longgang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperuricemia may occur when there is an excess of uric acid in the blood. Hyperuricemia may result from increased production or decreased excretion of uric acid. Elevated uric acid levels are a risk factor for gout, and various risk factors, including some medications, alcohol consumption, kidney disease, high blood pressure, hypothyroidism, and pesticide exposure, as well as obesity, are associated with an elevated risk of hyperuricemia. Although the mechanisms underlying the pathogenesis of hyperuricemia are complex, previously reported studies have revealed that hyperuricemia is involved in a variety of biological processes and signaling pathways. In this review, we summarize common comorbidities related to hyperuricemia and describe an update of epidemiology, pathogenesis, and therapeutic options of hyperuricemia. This systematic review highlights the epidemiology and risk factors of hyperuricemia. Moreover, we discuss genetic studies on hyperuricemia to uncover current status and advances in the pathogenesis of hyperuricemia. Additionally, we conclude with a reflection on the underlying mechanisms of hyperuricemia and present the alternative drug strategies for the treatment of hyperuricemia to offer more effective clinical interventions.

Indexed as

epidemiologygeneticsHyperuricemiamechanismstreatment

Identifiers

PMID32774692
PMCPMC7407685
OpenAlexW3049764131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.